Patients receiving chemotherapy in Lincolnshire can now have additional treatment to help reduce their hair loss. Many cancer ...

Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

A patient's delayed cancer diagnosis led to a medical malpractice lawsuit against her primary care doctor and endocrinologist ...

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...